Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 8Breast 5Other hematologic neoplasm 2Plasma cell 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1Anemia 1

Interventions

Cytarabine 10venetoclax 8Rituximab 7Daunorubicin 7nilotinib 6Azacitidine 6blinatumomab 5Bendamustine Hydrochloride 5bosutinib 4Imatinib Mesylate 4obinutuzumab 3asciminib 3acalabrutinib 3Mitoxantrone 3Methotrexate 3Etoposide 3Dexamethasone 3Decitabine 3Dasatinib 3zanubrutinib 2trametinib 2talquetamab 2revumenib 2pirtobrutinib 2pegaspargase 2ivosidenib 2idelalisib 2ibrutinib 2fludarabine 2decitabine and cedazuridine drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Cyclophosphamide × Other hematologic neoplasm × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡